What are the evidence‑based current recommendations for skin antisepsis in term neonates (≥37 weeks gestation), pre‑term infants (<34 weeks gestation or ≤1500 g), extremely pre‑term neonates (<28 weeks gestation or <1000 g), and children of any age?

Evidence-Based Recommendations for Skin Antisepsis in Neonates & Children

For term neonates and children, use 2% chlorhexidine gluconate in 70% alcohol for skin antisepsis; for infants under 2 months of age, use the minimum volume necessary while ensuring adequate antisepsis, and for extremely preterm neonates (<28 weeks gestation), avoid alcohol-based preparations due to burn risk and consider aqueous chlorhexidine or povidone-iodine with careful monitoring.

Agent Selection by Age and Gestational Age

Term Neonates (≥37 weeks) and Children

• Chlorhexidine in alcohol is superior to povidone-iodine for skin antisepsis, demonstrating faster onset, longer duration of action, and six-fold reduction in catheter colonization 1
• 2% chlorhexidine gluconate in 70% isopropyl alcohol shows maximum efficacy with optimal residual effect in term neonates, achieving 2.6 log reduction in bacterial counts with sustained effect at 6-24 hours 2
• This formulation outperforms both 70% isopropyl alcohol alone and 10% povidone-iodine 2
• All three antiseptics (2% CHG-IPA, povidone-iodine, alcohol) are skin-friendly in term neonates with no significant impact on skin integrity 2

Infants Under 2 Months of Age

• Use minimum volume of chlorhexidine necessary while ensuring antisepsis 1
• This recommendation balances efficacy against theoretical concerns about percutaneous absorption in immature skin
• Despite FDA non-approval for children <2 months, chlorhexidine is commonly used in neonatal intensive care units without significant adverse events when used judiciously 1

Preterm Infants (28-34 weeks gestation or ≤1500g)

• Aqueous chlorhexidine preparations are preferred over alcohol-based formulations to avoid skin burns
• 2% aqueous chlorhexidine is more effective than 1% aqueous chlorhexidine: 95.6% vs 93.0% sterile post-antisepsis cultures, though 1% was not proven non-inferior 3
• For central venous catheter insertion in preterm infants >28 weeks, 2% CHG in 70% IPA can be used with careful application technique and monitoring 4
• No severe skin lesions reported in infants >28 weeks gestation when using 2% CHG in 70% IPA with sterile pre-measured devices 4

Extremely Preterm Neonates (<28 weeks gestation or <1000g)

• Avoid alcohol-based chlorhexidine preparations - documented burns in infants 24-26 weeks gestational age 1
• Consider aqueous chlorhexidine or povidone-iodine as alternatives
• Use absolute minimum volume due to increased skin permeability and documented systemic absorption in infants <36 weeks gestation 1
• Two cases of severe skin lesions occurred with 2% CHG in 70% IPA in 24-week infants 4
• Monitor closely for contact dermatitis, particularly with prolonged chlorhexidine-impregnated dressings 1

Concentration Considerations

For procedures requiring neuraxial blockade or high-risk invasive procedures, prefer 0.5% chlorhexidine in alcohol over 2% concentration 1:

• No convincing evidence of antimicrobial superiority of 2% over 0.5%
• Clear evidence of neurotoxicity with chlorhexidine
• This reduces risk while maintaining efficacy

Critical Safety Measures

Application Technique

• Allow solution to completely dry before skin puncture - prevents chlorhexidine from tracking into deeper tissues 1
• Keep chlorhexidine away from drugs and equipment for invasive procedures
• Check gloves for contamination before proceeding
• Single spray application is sufficient; repeated applications increase contamination risk without improving efficacy 1

Monitoring Requirements

• Assess skin condition at 0,6,12, and 24 hours post-application
• Watch for erythema, dermatitis, or burns, particularly in preterm infants
• Be aware that transient alterations in skin hydration return to baseline within 6-24 hours 2

Common Pitfalls to Avoid

1. Using alcohol-based preparations in extremely preterm infants - high burn risk in infants <28 weeks
2. Excessive volume application in neonates <2 months - increases absorption risk without improving efficacy
3. Not allowing adequate drying time - creates tracking risk for invasive procedures
4. Assuming povidone-iodine is safer - actually has slower onset, shorter duration, and can cause reactive hypothyroidism through absorption 5
5. Using 2% concentration when 0.5% would suffice - unnecessarily increases neurotoxicity risk for neuraxial procedures

Evidence Gaps and Current Practice Variation

Current practice shows significant variation across neonatal intensive care units with limited standardized protocols 6. The main challenges identified include high skin vulnerability (87.5%), adhesive-related issues (72.9%), infection risk (64.5%), and unclear evidence (54.2%) 6. This underscores the need for individualized assessment within these evidence-based parameters, particularly for the most vulnerable extremely preterm population where high-quality data remains limited 7.